Compassionate Access Authorisation (AAC) is a regulatory pathway in France enabling patients with serious or rare conditions, who have no satisfactory therapeutic alternative, to benefit from innovative medicines prior to marketing approval.
Supervised by the French Medicines Agency (ANSM), it ensures patient safety while facilitating early access to treatments addressing urgent unmet medical needs.
For Cevidra, supporting companies in obtaining and managing AACs is a key expertise, helping biopharmaceutical partners make their innovative therapies rapidly available in France.
